Oliva, Stefania http://orcid.org/0000-0002-3084-180X
Bruinink, Davine Hofste op http://orcid.org/0000-0002-1296-120X
Rihova, Lucie
D’Agostino, Mattia
Pantani, Lucia
Capra, Andrea
van der Holt, Bronno
Troia, Rossella
Petrucci, Maria Teresa
Villanova, Tania
Vsianska, Pavla
Jugooa, Romana
Brandt-Hagens, Claudia
Gilestro, Milena
Offidani, Massimo
Ribolla, Rossella
Galli, Monica
Hajek, Roman
Gay, Francesca
Cavo, Michele
Omedé, Paola
van der Velden, Vincent H. J. http://orcid.org/0000-0001-9457-3763
Boccadoro, Mario http://orcid.org/0000-0001-8130-5209
Sonneveld, Pieter
Funding for this research was provided by:
Ministerstvo Zdravotnictví Ceské Republiky (17-30089A)
Article History
Received: 16 March 2021
Revised: 25 March 2021
Accepted: 12 April 2021
First Online: 3 June 2021
Conflict of interest
: S.O. has received honoraria from Amgen, Celgene, and Janssen; has served on the advisory boards for Adaptive Biotechnologies, Janssen, Amgen, and Takeda. M.D. has received honoraria for lectures from Sanofi; has served on the advisory board for GSK. L.P. has received honoraria from Celgene, Janssen, Amgen, Takeda. M.T.P. has received honoraria from and served on the advisory board for Celgene, Janssen-Cilag; Bristol-Myers-Squibb. Takeda, Amgen, Sanofi, GSK. M.O. has received honoraria from and served on the advisory board for Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Takeda. R.R. has served on the advisory board for Janssen. M.G. has received honoraria from Bristol-Myers-Squibb, Celgene, Janssen, Takeda. R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. F.G. has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, and GSK; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, GSK, Roche, Adaptive Biotechnologies, and Oncopeptides. M.C. has received honoraria from Janssen, Celgene, Amgen, Bristol- Myers Squibb, Takeda, AbbVie, Sanofi, and Adaptive Biotechnologies, and is a member of speakers’ bureaus for Janssen and Celgene. V.H.J.v.d.V. has Laboratory Service Agreements with Pfizer, Janssen, Novartis/Navigate, BD Biosciences; and is the inventor of the EuroFlow-owned patents PCT/NL2010/050332 and PCT/NL2013/0505420. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. P.S. received honoraria from and research funding from Amgen, Celgene, Janssen, SkylineDx, and Takeda. All the other authors have no conflicts of interest.